Chemistry:SC-4289

From HandWiki

SC-4289 is a synthetic nonsteroidal estrogen which, along with mytatrienediol (SC-6924; Manvene, Anvene), was developed in the late 1950s as a potential treatment for atherosclerosis in men but was never marketed.[1][2]

The chemical structure of SC-4289 is the same as for methallenestril but differs in that it is the benzyl ether and not the methyl ether.

SC-4289 makes an appearance in the allenestrol patent,[3] as well as a stand-alone compound in:[4]

References

  1. Cite error: Invalid <ref> tag; no text was provided for refs named RobinsonCohen1956
  2. "Experimental hormonal therapy of atherosclerosis: preliminary observations on the effects of two new compounds". Am. J. Med. Sci. 235 (1): 50–9. 1958. doi:10.1097/00000441-195801000-00006. PMID 13487586. 
  3. Raymond M Dodson & Paul B Sollman, U.S. Patent 3,014,076 (1961 to GD Searle LLC).
  4. Raymond M Dodson & Paul B Sollman, U.S. Patent 2,831,887 (1958 to GD Searle LLC).